Biosergen AB

Equities

BIOSGN

SE0016013460

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 15:07:11 17/05/2024 BST			5-day change	1st Jan Change
0.297 ^SEK	-0.67%		-4.50%	-66.25%

04-09	Biosergen to Issue New Units as Compensation Under Rights Issue	MT
03-27	Biosergen Raises SEK26.4 Million via Rights Issue	MT

Biosergen CEO to BioStock: "Positive data give us a strong value proposition"

March 07, 2024 at 07:46 am

Biosergen is carrying out a SEK 40.5 million rights issue to conduct a first-in-patient safety and efficacy study with the antifungal drug candidate BSG005. This will set the stage for the phase II and III clinical studies, which will be financed and undertaken in collaboration with the Indian partner, Alkem. BioStock contacted Biosergen CEO Tine Kold Olesen to get more insights.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/biosergen-ceo-positive-data-give-us-a-strong-value-proposition/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/biosergen-ab/r/biosergen-ceo-to-biostock---positive-data-give-us-a-strong-value-proposition-,c3941150

Latest news about Biosergen AB

Biosergen to Issue New Units as Compensation Under Rights Issue	04-09	MT
Biosergen Raises SEK26.4 Million via Rights Issue	03-27	MT
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	02-12	MT
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	02-12	CI
Biosergen Seeks Fresh Funds from Rights Offering, Secures Loan from Major Shareholder	01-31	MT
Biosergen AB Announces CEO Changes	01-12	CI
Biosergen AB Announces Transition of Peder M. Andersen into A Chief Medical Officer Role	01-12	CI
Biosergen Conducts A New Phase 1B Study in Patients with Invasive Fungal Infections with Its Drug Candidate Bsg005 Together with Alkem	01-12	CI
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate	12-12	MT
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30	CI
Biosergen AB Announces Abstract About the Drug Candidate BSG005	23/10/23	CI
Certain Shares of Biosergen AB are subject to a Lock-Up Agreement Ending on 4-OCT-2023.	03/10/23	CI
Biosergen, Alkem Laboratories Partner to Launch Clinical Trial of Fungal Disease Treatment in India	25/09/23	MT
Alkem Laboratories Limited and Biosergen AB Enter into a Co-Development and License Agreement	25/09/23	CI
Biosergen AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Biosergen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23	CI
Biosergen AB Announces Lena Degling Wikingsson and Hanne Mette Dyrlie Kristensen Declines Re-Election as Board Members	31/05/23	CI
Biosergen Provides Phase 2 Clinical Development Strategy Update	29/03/23	CI
Biosergen AB announces Positive Topline Data from Phase 1 Study of Bsg005 Shows It Is Safe and Well Tolerated. It Gives Hope for A Change in the Treatment Paradigm of Patients with Invasive Fungal Infections	13/03/23	CI
Biosergen Proceeds with Phase 1 Anti-Fungal Drug Trial	16/01/23	MT
Biosergen Completes the First Multiple Ascending Dose Cohort of BSG005 Phase I Trial	16/01/23	CI
Biosergen Rises 16% on Progress of Clinical Trial for Antifungal Drug Candidate	12/12/22	MT
Biosergen AB Announcest First Volunteer Has Been Dosed in the Mad Part of the Phase I Trial of BSG005	12/12/22	CI
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	30/11/22	CI

Chart Biosergen AB

Duration

Period

More charts

Company Profile

Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOSERGEN AB	-66.25%	3.95M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs